TABLE 2.
Association of patient and tumor characteristics following neoadjuvant chemotherapy and pathologic complete response (pCR) versus no pCR
| Characteristic | pCR, n = 26 | No pCR, n = 125 | P-Value |
|---|---|---|---|
| Age (years) | |||
| < 50 | 11 (42) | 71 (57) | NS |
| ≥50 | 15 (58) | 54 (43) | |
| Race | |||
| Caucasian | 14 (54) | 75 (60) | NS |
| African–American | 11 (42) | 46 (37) | |
| Other | 1 (4) | 4 (3) | |
| Clinical T stage | |||
| T1 | 5 (19) | 17 (14) | NS |
| T2 | 17 (65) | 58 (46) | |
| T3 | 2 (8) | 22 (17) | |
| T4 | 2 (8) | 20 (16) | |
| Unknown | 0 | 8 (6) | |
| Histology | |||
| Invasive ductal | 22 (85) | 98 (78) | NS |
| Invasive lobular | 1 (4) | 6 (5) | |
| Mixed/others | 3 (11) | 21 (17) | |
| Nuclear grade | |||
| Grade 1 | 0 (0) | 2 (2) | NS |
| Grade 2 | 1 (4) | 14 (11) | |
| Grade 3 | 24 (92) | 106 (85) | |
| Unknown | 1 (4) | 3 (2) | |
| Clinical N status | |||
| N0 | 13 (50) | 50 (40) | NS |
| N1 | 9 (35) | 56 (45) | |
| N2 | 0 (0) | 9 (7) | |
| N3 | 5 (15) | 6 (5) | |
| Unknown | 0 (0) | 4 (3) | |
| Clinical stage | |||
| 1 | 4 (15) | 6 (5) | NS |
| 2A | 11 (42) | 40 (32) | |
| 2B | 6 (23) | 28 (22) | |
| 3 | 5 (19) | 44 (35) | |
| Unknown | 0 | 7 (6) | |